CARGO Therapeutics (NASDAQ:CRGX) & OKYO Pharma (NASDAQ:OKYO) Head to Head Survey

OKYO Pharma (NASDAQ:OKYO) and CARGO Therapeutics (NASDAQ:CRGX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Profitability

This table compares OKYO Pharma and CARGO Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
OKYO Pharma	N/A	N/A	N/A
CARGO Therapeutics	N/A	-38.16%	-33.94%

Analyst Recommendations

This is a summary of current ratings and target prices for OKYO Pharma and CARGO Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OKYO Pharma	0	0	1	0	3.00
CARGO Therapeutics	1	6	0	0	1.86

OKYO Pharma currently has a consensus target price of $7.00, suggesting a potential upside of 548.15%. CARGO Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 284.62%. Given OKYO Pharma’s stronger consensus rating and higher probable upside, equities analysts clearly believe OKYO Pharma is more favorable than CARGO Therapeutics.

Valuation & Earnings

This table compares OKYO Pharma and CARGO Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A
CARGO Therapeutics	N/A	N/A	-$98.15 million	($4.26)	-0.92

Institutional & Insider Ownership

3.0% of OKYO Pharma shares are owned by institutional investors. Comparatively, 93.2% of CARGO Therapeutics shares are owned by institutional investors. 40.5% of OKYO Pharma shares are owned by company insiders. Comparatively, 1.4% of CARGO Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

OKYO Pharma has a beta of -0.27, suggesting that its share price is 127% less volatile than the S&P 500. Comparatively, CARGO Therapeutics has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500.

Summary

OKYO Pharma beats CARGO Therapeutics on 7 of the 9 factors compared between the two stocks.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

About CARGO Therapeutics

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.